ReviewCancer metastasis reviews2026
Obesity and melanoma: unraveling the paradoxical survival benefit in immunotherapy.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of melanoma has been steadily increasing worldwide, with metastatic disease accounting for a substantial proportion of melanoma-related deaths. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for advanced melanoma, yet patient responses remain highly variable. Interestingly, although obesity is a well-established risk factor for the development of melanoma, paradoxically, emerging clinical data reveal that obese patients may experience superior outcomes following ICI therapy-a phenomenon commonly referred to as the "obesity paradox". The biological mechanisms underpinning this paradox remain incompletely elucidated. This review synthesizes current evidence through a critical examination of methodologies used to define obesity in oncology research, followed by an exploration of mechanistic links between obesity and melanomagenesis. We subsequently summarize clinical evidence supporting the obesity paradox in melanoma immunotherapy and discuss potential immune-mediated and metabolic mechanisms underlying this paradoxical association. The review concludes by addressing translational implications of these findings for patient stratification and novel therapeutic strategies.
Indexed as
Identifiers
41792481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.